Dose and frequency in cancer therapy. Theoretical non-autonomous model of p53 network

References

• Batchelor E, Loewer A. 2017. Recent progress and open challenges in modeling p53 dynamics in single cells. Curr Opin Syst Biol. 3:54–59.10.1016/j.coisb.2017.04.007
   PubMedGoogle Scholar
• Betancourt-Mar JA. 2005. The Rössler system as a model for chronotherapy. J Phys: Conf Ser. IOP Publishing.
   Google Scholar
• Betancourt-Mar JA, Alarcón-Montelongo IS, Nieto-Villar JM. 2006. Theoretical models in chronotherapy: II. Periodic perturbations in a chaotic chemical reaction. Biol Rhythm Res. 37(2):131–136.10.1080/09291010500332083
   Web of Science ®Google Scholar
• Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. 2009. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 9(12):862.10.1038/nrc2763
   PubMed Web of Science ®Google Scholar
• Carvajal LA, Manfredi JJ. 2013. Another fork in the road – life or death decisions by the tumour suppressor p53. EMBO Rep. 14(5):414–421.10.1038/embor.2013.25
   PubMed Web of Science ®Google Scholar
• Ciliberto A, Novak B, Tyson JJ. 2005. Steady states and oscillations in the p53/Mdm2 network. Cell Cycle. 4(3):488–493.10.4161/cc.4.3.1548
   PubMed Web of Science ®Google Scholar
• Dallmann R, Okyar A, Lévi F. 2016. Dosing-time makes the poison: circadian regulation and pharmacotherapy. Trends Mol Med. 22(5):430–445.10.1016/j.molmed.2016.03.004
   PubMed Web of Science ®Google Scholar
• Deisboeck T, Berens M, Kansal A, Torquato S, Stemmer-Rachamimov A, Chiocca E. 2001. Pattern of self-organization in tumour systems: complex growth dynamics in a novel brain tumour spheroid model. Cell Prolif. 34(2):115–134.10.1046/j.1365-2184.2001.00202.x
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. 2000.The hallmarks of cancer. Cell. 100(1):57–70.10.1016/S0092-8674(00)81683-9
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. 2011.Hallmarks of cancer: the next generation. Cell. 144(5):646–674.10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH. 2003. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 21(6):976–983.10.1200/JCO.2003.02.063
   PubMed Web of Science ®Google Scholar
• Hoops S, Sahle S, Gauges R, Lee C, Pahle J, Simus N, Singhal M, Xu L, Mendes P, Kummer U. 2006. COPASI--a COMPLEX PAthway SImulator. Bioinformatics. 22(24):3067–3074.10.1093/bioinformatics/btl485
   PubMed Web of Science ®Google Scholar
• Hu J, Gao J, Principe JC. 2006. Analysis of biomedical signals by the Lempel-Ziv complexity: the effect of finite data size. IEEE Trans Biomed Eng. 53(12):2606–2609.
   PubMed Web of Science ®Google Scholar
• Izquierdo-Kulich E, Nieto-Villar JM. 2011. A mesoscopic approach to model regulation of apoptosis by p53. Revista Cubana de Física. 28(2):119–122.
   Google Scholar
• Jackson JG, Post SM, Lozano G. 2011. Regulation of tissue-and stimulus-specific cell fate decisions by p53 in vivo. J Pathol. 223(2):127–137.10.1002/path.2783
   PubMed Web of Science ®Google Scholar
• Kitano H. 2007. Towards a theory of biological robustness. Mol Syst Biol. 3(1):137.
   PubMedGoogle Scholar
• Lahav G, Rosenfeld N, Sigal A, Geva-Zatorsky N, Levine AJ, Elowitz MB, Alon U. 2004. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet. 36(2):147.10.1038/ng1293
   PubMed Web of Science ®Google Scholar
• Lane DP. 1992. p53, guardian of the genome. Nature. 358:15–16.10.1038/358015a0
   PubMed Web of Science ®Google Scholar
• Lempel A, Ziv J. 1976. On the complexity of finite sequences. IEEE Trans Inf Theory. 22(1):75–81.10.1109/TIT.1976.1055501
   Web of Science ®Google Scholar
• Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88(3):323–331.10.1016/S0092-8674(00)81871-1
   PubMed Web of Science ®Google Scholar
• Luo Q, Beaver JM, Liu Y, Zhang Z. 2017. Dynamics of p53: a master decider of cell fate. Genes. 8(2):66.10.3390/genes8020066
   PubMed Web of Science ®Google Scholar
• Montero F, Morán F. 1992. Biofísica: Procesos de autoorganización en Biología. 577(3).
   Google Scholar
• Mormont MC, Levi F. 2003. Cancer chronotherapy: principles, applications, and perspectives. Cancer. 97(1):155–169.10.1002/(ISSN)1097-0142
   PubMed Web of Science ®Google Scholar
• Nieto-Villar J, Izquierdo-Kulich E, Betancourt-Mar JA, Tejera E. 2013. UH, editor. Complejidad y autoorganización de patrones naturales. Havana, Cuba.
   Google Scholar
• Proctor CJ, Gray DA. 2008. Explaining oscillations and variability in the p53-Mdm2 system. BMC Syst Biol. 2(1):75.10.1186/1752-0509-2-75
   PubMedGoogle Scholar
• Purvis JE, Karhohs KW, Mock C, Batchelor E, Loewer A, Lahav G. 2012. p53 Dynamics control cell fate. Science. 336(6087):1440–1444.10.1126/science.1218351
   PubMed Web of Science ®Google Scholar
• Rockmore D. 2005. Cancer complex nature. Santa Fe Inst Bull. 20:18–21.
   Google Scholar
• Salazar C, Garcia L, Rodriguez Y, Garcia J, Quintana R, Rieumont J, Nieto-Villar J. 2003. Theoretical models of chronotherapy: I. Periodic perturbations in oscillating chemical reactions. Biol Rhythm Res. 34(3):241–249.10.1076/brhm.34.3.241.18813
   Web of Science ®Google Scholar
• Schwab E, Pienta KJ. 1996. Cancer as a complex adaptive system. Med Hypotheses. 47(3):235–241.10.1016/S0306-9877(96)90086-9
   PubMed Web of Science ®Google Scholar
• Selfridge JM, Gotoh T, Schiffhauer S, Liu J, Stauffer PE, Li A, Capelluto DG, Finkielstein CV. 2016. Chronotherapy: intuitive, sound, founded…but not broadly applied. Drugs. 76(16):1507–1521.10.1007/s40265-016-0646-4
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature. 408(6810):307.10.1038/35042675
   PubMed Web of Science ®Google Scholar
• Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC. 2004. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia Group B trial 9342. J Clin Oncol. 22(11):2061–2068.10.1200/JCO.2004.08.048
   PubMed Web of Science ®Google Scholar